SPACs: An Alternative to Life Sciences & Healthcare IPOs
With $19+ billion in proceeds raised year-to-date, SPACs—an alternative means of going public—are a dominant presence in the IPO market. While the IPO market has generally remained open to life science and healthcare companies in 2020 despite the global pandemic, SPACs are increasingly becoming the preferred path to the public markets for many companies.
Please join us as we discuss with George Kaufman, Head of Investment Banking Chardan—an independent, global investment bank specializing in healthcare, disruptive technologies and SPACs:
- pros and cons of SPAC mergers relative to traditional IPOs;
- stage of development/IPO readiness requirements for a SPAC mergers;
- processes/timelines for SPAC mergers versus traditional IPOs;
- trends in life science and healthcare SPAC M&A.
Yelena Dunaevsky, Transactional Insurance Executive at Woodruff Sawyer, will also discuss the use of representation & warranty insurance in SPAC M&A.